The FDA/industry-negotiated agreement to renew the biosimilar user fee program provides too much lag time for issuing and finalizing key guidance documents, representatives from consumer and professional groups said at an Oct. 20 meeting.
However, the agreement’s target dates for a long-delayed draft guidance on interchangeability, and final guidance documents on nonproprietary naming and labeling, seemed to be the biggest complaints leveled against the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?